Evaluation and management of peripheral neuropathy in diabetic patients with cancer

Clinical Journal of Oncology Nursing

Volumn 12, Issue 2, 2008, Pages 243-247

  Visovsky, Constance ^a   Meyer, Rachel R ^a   Roller, Jeffre ^a   Poppas, Megan ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

COMORBIDITY; DIABETIC NEUROPATHY; DRUG MONITORING; HOSPITALIZATION; HUMAN; INCIDENCE; METHODOLOGY; NEOPLASM; NEUROLOGIC EXAMINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSING; NURSING ASSESSMENT; ONCOLOGY NURSING; PATIENT EDUCATION; PERIPHERAL NEUROPATHY; REVIEW; SAFETY;

ANTINEOPLASTIC AGENTS; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DRUG MONITORING; HUMANS; INCIDENCE; NEOPLASMS; NEUROLOGIC EXAMINATION; NURSING ASSESSMENT; ONCOLOGIC NURSING; PATIENT EDUCATION AS TOPIC; PERIPHERAL NERVOUS SYSTEM DISEASES; SAFETY MANAGEMENT; SEVERITY OF ILLNESS INDEX;

EID: 45549103595     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/08.CJON.243-247     Document Type: Review

References (33)

1. Almadrones, L., Armstrong, T., Gilbert, M., & Schwartz, R. (2002). Chemotherapy-induced neurotoxicity. Philadelphia: Phillips Group Oncology.
2. Almadrones, L., McGuire, D.B., Walczak, J.R., Florio, C.M., & Tian, C. (2004). Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: A Gynecologic Oncology Group study. Oncology Nursing Forum, 31(3), 615-623.
3. American Diabetes Association. (2002). Standards of medical care for patients with diabetes mellitus. Diabetes Care, 25, S33-S49.
4. Andersen, H., Nielsen, S., Mogensen, C., & Jakobsen, J. (2004). Muscle strength in type 2 diabetes. Diabetes, 53(6), 1543-1548.
5. Argoff, C.E., Cole, B.E., Fishbain, D.A., & Irving, G.A. (2006). Diabetic peripheral neuropathic pain: Clinical and quality-of-life issues. Mayo Clinic Proceedings, 81(4, Suppl.), S3-S11.
6. Aring, A.M., Jones, D.E., & Falko, J.M. (2005). Evaluation and prevention of diabetic neuropathy. American Family Physician, 71 (11), 2123-2128.
7. Boya, F., Laruant, B., Pajouhi, M., Lofti, J., Noraii, M.M., & Bandar-ian, F. (2003). Peripheral neuropathy in diabetic patients and its contributing factors. Iranian Journal of Diabetes and Lipid Disorders, 3(1), 41-46.
8. Calhoun, E.A., Welshman, E.E., Chang, C.H., Lurain, J.R., Fishman, D.A., Hunt, T.L., et al. (2003). Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. International Journal of Gynecological Cancer, 13(6), 741-748.
9. Cavaletti, G., Bogliun, G., Marzorati, L., Zincone, A., Piatti, M., Colombo, N., et al. (2003). Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology, 61(9), 1297-1300.
10. Cella, D., Peterman, A., Hudgens, S., Webster, K., & Socinski, M. (2003). Measuring the side effects of taxane therapy in oncology: The Functional Assessment of Cancer Therapy-Taxane (FACT-Taxane). Cancer, 98(4), 822-831.
11. Dippel, E., Zouboulis, C.C., Tebbe, B., & Orfanos, C.E. (1998). Myo-pathic syndrome associated with long-term recombinant inter-feron alfa treatment in 4 patients with skin disorders. Archives of Dermatology, 134(7), 880-881.
12. Dobretsov, M., Romanovsky, D., & Stimers, J.R. (2007). Early diabetic neuropathy: Triggers and mechanisms. World Journal of Gastroenterology, 13(2), 175-191.
13. Dyck, P.J., Litchy, W.J., Lehman, K.A., Hokanson, J.L., Low, P.A., & O'Brien, P.C. (1995). Variables infuencing neuropathic end-points: The Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology, 45(6), 1115-1121.
14. Gore, M., Brandenburg, N.A., Dukes, E., Hoffman, D.L., Tai, K.S., & Stacey, B. (2005). Pain severit y in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. Journal of Pain and Symptom Management, 30(4), 374-385.
15. Hausheer, F.H., Schilsky, R.L., Bain, S., Berghorn, E.J., & Lieber-man, F. (2006). Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology, 33(1), 15-49.
16. Herman, W.H., & Kennedy, L. (2005). Underdiagnosis of peripheral neuropathy in type 2 diabetes. Diabetes Care, 28(6), 1480-1481.
17. Kasper, C.E., & Sarna, L. (2000). The infuence of adjuvant chemotherapy on skeletal muscle and fatigue in women with breast cancer. Biological Research for Nursing, 2(2), 133-139.
18. Kastenbauer, T., Irsigler, P., Sauseng, S., Grimm, A., & Preger, R. (2004). The prevalence of symptoms of sensorimotor and auto-nomic neuropathy in type 1 and type 2 diabetic subjects. Journal of Diabetes and Its Complications, 18(1), 27-31.
19. Low, P.A., Nickander, K.K., & Scionti, L. (1999). Role of hypoxia,
20. oxidative stress, and excitator y neurotoxi ns in diabetic neuropathy. In P.J. Dyck & P.K. Thomas (Eds.), Diabetic neuropathy (2nd ed., pp. 317-329). Philadelphia: W.B. Saunders.
21. Nicolucci, A., Carinci, F., Graepel, J., Hohman, T., Ferris, F., & Lachin, J. (1996). The effcacy of tolrestat in the treatment of diabetic peripheral neuropathy: A meta-analysis of individual patient data. Diabetes Care, 19(10), 1091-1095.
22. Padua, L., Schenone, A., Aprile, I., Benedetti, L., Caliandro, P., Tonali, P., et al. (2005). Quality of life and disability assessment in neuropathy: A multicentre study. Journal of the Peripheral Nervous System, 10(1), 3-10.
23. Psarakis, H. (2006). Clinical challenges in caring for patients with diabetes and cancer. Diabetes Spectrum, 19(3), 157-162.
24. Raccah, D., Fabregueettes, C., Azulay, J.P., & Vague, P. (1996). Erythrocyte Na(+)-K(+)-ATPase activity, metabolic control, and neuropathy in IDDM patients. Diabetes Care, 19(6), 564-568.
25. Shy, M.E., Frohman, E.M., So, Y.T., Arezzo, J.C., Cornblath, D.R., Giuliani, M.J., et al. (2003). Quantitative sensory testing: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 60(6), 898-904.
26. Sweeney, C.W. (2002). Understanding peripheral neuropathy in patients with cancer: Background and patient assessment. Clinical Journal of Oncology Nursing, 6(3), 163-166.
27. Tobin, K., Giuliani, M.J., & Lacomis, D. (1999). Comparison of different modalities for detection of small fber neuropathy. Clinical Neurophysiology, 110(11), 1909 -1912.
28. Veves, A., & Sarnow, M. (1995). Diagnosis, classifcation, and treatment of diabetic peripheral neuropathy. Clinics in Podiatric Medicine and Surgery, 12(1), 19-30.
29. Visovsky, C. (2003). Chemotherapy-induced peripheral neuropathy. Cancer Investigation, 21(3), 439-451.
30. Visovsky, C. (2006). The effects of neuromuscular alterations in elders with cancer. Seminars in Oncology Nursing, 22(1), 36-42.
31. ®: Evidence-based inter ven-tions for chemotherapy-induced peripheral neuropathy. Clinical Journal of Oncology Nursing, 11(6), 901-913.
32. Wampler, M.A., Hamolsky, D., Hamel, K., Melisko, M., & Topp, K. (2005). Case report: Painful peripheral neuropathy following treatment with docetaxel for breast cancer. Clinical Journal of Oncology Nursing, 9(2), 189-193.
33. Wickham, R. (2007). Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. Clinical Journal of Oncology Nursing, 11 (3), 361-376.